Sign in Subscribe
Cancer

Lenvatinib Plus Pembrolizumab Shows Promising Results in Advanced Endometrial Cancer Treatment

Strategic Insights

— 1 min read

Recent research has shed light on the efficacy and safety of a new treatment regimen for advanced endometrial cancer (aEC). The study, conducted by researchers at Texas Tech University Health Sciences Center, compared the use of lenvatinib combined with pembrolizumab (LVB + PMB) to chemotherapy in patients with aEC. The findings suggest that LVB + PMB shows superior progression-free survival in second-line settings, but its first-line application in unselected populations remains inconclusive. This has significant implications for the evolving therapeutic landscape of aEC, highlighting the need for strategic patient stratification and biomarker development to maximize clinical outcomes.

Key Takeaways:

  • Advanced endometrial cancer (aEC) presents a formidable therapeutic challenge, particularly in patients with recurrent or metastatic disease.
  • Historically, platinum-based chemotherapy has been the mainstay treatment for aEC, but the treatment paradigm has shifted with the emergence of immune checkpoint inhibitors (ICIs) and targeted therapies.
  • Lenvatinib combined with pembrolizumab (LVB + PMB) has emerged as a promising regimen, particularly for patients with proficient mismatch repair (pMMR) tumors.
  • The KEYNOTE-775 and LEAP-001 trials have highlighted the efficacy and safety of LVB + PMB in patients with aEC.
  • Strategic patient stratification and biomarker development are key to maximizing clinical outcomes in aEC treatment.
  • The molecular and immunologic landscape of aEC provides a mechanistic rationale for treatment response and resistance.
  • The research also explores future research directions, including novel combinations and biomarkers, and provides recommendations for the evolving therapeutic landscape.

Statistics:

  • 17% increase in progression-free survival in second-line settings using LVB + PMB compared to chemotherapy (KEYNOTE-775 trial).
  • 35% response rate in pMMR tumors to LVB + PMB in the LEAP-001 trial.
  • 50% of patients with aEC have proficient mismatch repair (pMMR) tumors.
  • The majority of patients with aEC respond poorly to ICI monotherapy.

Sources:

  • NewsRx. Researchers from Texas Tech University Health Sciences Center Report Findings in Endometrial Cancer (Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights). Immunotherapy Weekly. September 17, 2025; p 1442.
  • Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights. Cureus, 2025;17(7).

Read more